Low RKIP expression associates with poor prognosis in bladder cancer patients

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author AFONSO, Julieta
LOBO, Francisco
AMARO, Teresina
REIS, Rui M.
SANTOS, Lucio L.
dc.date.issued 2013
dc.identifier.citation VIRCHOWS ARCHIV, v.462, n.4, p.445-453, 2013
dc.identifier.issn 0945-6317
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/5519
dc.description.abstract Urothelial bladder cancer (UBC) is a heterogeneous type of disease. It is urgent to screen biomarkers of tumour aggressiveness in order to clarify the clinical behaviour and to personalize therapy in UBC patients. Raf kinase inhibitory protein (RKIP) is a metastasis suppressor, and its downregulation is associated with metastatic events in an increasing number of solid tumours. We evaluated the clinical and prognostic significance of RKIP expression in patients with high risk of progression UBC. Using immunohistochemistry, we determined RKIP expression levels in a series of 81 patients with high-grade pT1/pTis or muscle-invasive UBC. Staining of CD31 and D2-40 was used to assess blood and lymphatic vessels, in order to distinguish between blood and lymphatic vessel invasion (LVI). We found that 90 % of pT1/pTis tumours, 94 % of non-muscle invasive papillary tumours and 76 % of the cases without LVI occurrence expressed RKIP in > 10 % of cells. In this group, we observed a subgroup of tumours (42 %) in which the tumour centre was significantly more intensely stained than the invasion front. This heterogeneous pattern was observed in 63 % of the cases with LVI. Low RKIP expression was associated with poorer 5-year disease-free and overall survival rates, and remained as an independent prognostic factor for disease-free survival. Loss of RKIP expression may be an important prognostic factor for patients with high risk of progression bladder cancer.
dc.language.iso eng
dc.publisher SPRINGER
dc.relation.ispartof Virchows Archiv
dc.rights restrictedAccess
dc.subject Bladder cancer; Biomarkers; RKIP; Lymphovascular invasion; Prognosis
dc.subject.other kinase inhibitor protein; nf-kappa-b; squamous-cell carcinoma; prostate-cancer; breast-cancer; mesenchymal transition; braf gene; raf; metastasis; invasion
dc.title Low RKIP expression associates with poor prognosis in bladder cancer patients
dc.type article
dc.rights.holder Copyright SPRINGER
dc.description.group LIM/14
dc.identifier.doi 10.1007/s00428-013-1388-2
dc.identifier.pmid 23462986
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author LONGATTO-FILHO, Adhemar:HC:LIM/14
hcfmusp.author.external · AFONSO, Julieta:Univ Minho, Life & Hlth Sci Res Inst ICVS, Braga, Portugal; ICVS 3Bs PT Govt Associate Lab, Braga, Portugal
· MARTINHO, Olga:Univ Minho, Life & Hlth Sci Res Inst ICVS, Braga, Portugal; ICVS 3Bs PT Govt Associate Lab, Braga, Portugal
· LOBO, Francisco:Portuguese Inst Oncol IPO, Dept Urol, P-4200072 Oporto, Portugal
· AMARO, Teresina:Portuguese Inst Oncol IPO, Expt Pathol & Therapeut Res Ctr, P-4200072 Oporto, Portugal
· REIS, Rui M.:Univ Minho, Life & Hlth Sci Res Inst ICVS, Braga, Portugal; ICVS 3Bs PT Govt Associate Lab, Braga, Portugal; Barretos Canc Hosp, Mol Oncol Res Ctr, Sao Paulo, Brazil
· SANTOS, Lucio L.:Portuguese Inst Oncol IPO, Dept Surg Oncol, P-4200072 Oporto, Portugal; Univ Fernando Pessoa UFP, Oporto, Portugal
hcfmusp.origem.id WOS:000317856400009
hcfmusp.origem.id 2-s2.0-84876502122
hcfmusp.publisher.city NEW YORK
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Afonso J, 2009, HISTOPATHOLOGY, V55, P514, DOI 10.1111/j.1365-2559.2009.03425.x
· Al-Mulla F, 2006, J CLIN ONCOL, V24, P5672, DOI 10.1200/JCO.2006.07.5499
· Al-Mulla F, 2008, J CLIN PATHOL, V61, P524, DOI 10.1136/jcp.2007.046987
· ALMULLA F, 2011, MOL BIOSYST, V7, P928, DOI 10.1039/C0MB00208A
· Al-Mulla F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029532
· Al-Mulla F, 2011, CANCER RES, V71, P1334, DOI 10.1158/0008-5472.CAN-10-3102
· Baritaki S, 2009, ONCOGENE, V28, P3573, DOI 10.1038/onc.2009.214
· Beach S, 2008, ONCOGENE, V27, P2243, DOI 10.1038/sj.onc.1210860
· Beshir AB, 2010, CANCER LETT, V299, P137, DOI 10.1016/j.canlet.2010.08.012
· Bevilacqua E, 2012, INT J BREAST CANC, V2012
· Boulalas I, 2009, INT J BIOL MARKER, V24, P17
· Chatterjee D, 2004, J BIOL CHEM, V279, P17515, DOI 10.1074/jbc.M313816200
· Chatterjee D, 2008, CLIN CANCER RES, V14, P2994, DOI 10.1158/1078-0432.CCR-07-4496
· Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294
· Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
· Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
· Eves EM, 2006, MOL CELL, V23, P561, DOI 10.1016/j.molcel.2006.07.015
· Fu Z, 2006, PROSTATE, V66, P248, DOI 10.1002/pros.20319
· Fu Z, 2003, J NATL CANCER I, V95, P878
· Gao CC, 2012, PATHOL ONCOL RES, V18, P471, DOI 10.1007/s12253-011-9470-z
· Grewal NK, 2008, INT J RADIAT ONCOL, V72, P153, DOI 10.1016/J.IJROBP.2008.04.072
· Hagan S, 2005, CLIN CANCER RES, V11, P7392, DOI 10.1158/1078-0432.CCR-05-0283
· Hao CF, 2012, TUMOR BIOL, V33, P1159, DOI 10.1007/s13277-012-0358-7
· Hellmann J, 2010, DEV NEUROSCI-BASEL, V32, P33, DOI 10.1159/000236595
· Hu CJ, 2011, J INT MED RES, V39, P229
· Karlou M, 2009, PATHOLOGY, V41, P327, DOI 10.1080/00313020902885011
· Kaufman DS, 2009, LANCET, V374, P239, DOI 10.1016/S0140-6736(09)60491-8
· Kim HS, 2012, PATHOL RES PRACT, V208, P292, DOI 10.1016/j.prp.2012.02.011
· Kim HS, 2010, HUM PATHOL, V41, P1609, DOI 10.1016/j.humpath.2010.04.012
· Kim HS, 2012, VIRCHOWS ARCH, V460, P61, DOI 10.1007/s00428-011-1174-y
· Kim HS, 2010, PATHOLOGY, V42, P655, DOI 10.3109/00313025.2010.522172
· Kim SY, 2011, J MICROBIOL BIOTECHN, V21, P525, DOI 10.4014/jmb.1012.12023
· Klysik J, 2008, CELL SIGNAL, V20, P1, DOI 10.1016/j.cellsig.2007.07.003
· Lee HC, 2006, GASTROENTEROLOGY, V131, P1208, DOI 10.1053/j.gastro.2006.07.012
· Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407
· Li HZ, 2008, MOL CANCER RES, V6, P917, DOI 10.1158/1541-7786.MCR-08-0093
· Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158
· Martinho O, 2009, VIRCHOWS ARCH, V455, P277, DOI 10.1007/s00428-009-0821-z
· Martinho O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030769
· Martinho O, 2012, J CLIN PATHOL, V65, P122, DOI 10.1136/jclinpath-2011-200358
· Minoo P, 2006, GUT, V55, DOI 10.1136/gut.2005.082859
· Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546
· Ruan L, 2010, J CELL BIOCHEM, V110, P975, DOI 10.1002/jcb.22611
· Schuierer MM, 2004, CANCER RES, V64, P5186, DOI 10.1158/0008-5472.CAN-03-3861
· Sternberg CN, 2006, ANN ONCOL S10, V17, P23
· Sternberg CN, 2007, UROLOGY, V69, P62, DOI 10.1016/j.urology.2006.10.041
· Stoehr R, 2004, ONCOL REP, V11, P137
· Tang HH, 2010, FEBS LETT, V584, P662, DOI 10.1016/j.febslet.2009.12.051
· Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110
· Wang J, 2010, MED ONCOL, V27, P219, DOI 10.1007/s12032-009-9194-z
· Wu K, 2009, CRIT REV IMMUNOL, V29, P241
· Xinzhou H, 2011, Mol Biol (Mosk), V45, P1004
· Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000
· Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001
· Yun JU, 2011, EMBO J, V30, P4500, DOI 10.1038/emboj.2011.312
· ZARAVINOS A, 2011, PATHOL ONCOL RES, V17, P181, DOI 10.1007/S12253-010-9295-1
· Zhang LZ, 2004, SURGERY, V136, P708, DOI 10.1016/j.surg.2003.12.013
· Zhu ST, 2005, CHEM BIOL, V12, P981, DOI 10.1016/j.chembiol.2005.07.007
dc.description.index MEDLINE
hcfmusp.citation.scopus 9
hcfmusp.citation.wos 9
hcfmusp.affiliation.country Brasil
hcfmusp.affiliation.country Portugal

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account